August 13, 2019
The ever-changing Canadian health care environment has forced the
pharmaceutical industry to rethink external deployment.
August 9, 2019
Health Canada Officials provided an update today regarding the final Patented Medicines Regulations.
August 1, 2019
“Canada does not support actions that could adversely affect the supply of prescription drugs in Canada and potentially raise costs of prescription drugs for Canadians.”
July 12, 2019
The draft Guidance document regarding The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products has been posted by Health Canada.
July 9, 2019
The Regulations regarding mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) by hospitals, proposed last summer, have now been adopted and will come into effect by December 16, 2019.
June 25, 2019
The Federal Court has dismissed Alexion’s request to review the PMPRB’s decision that SOLIRIS’ price was excessive.
June 25, 2019
Canada Gazette, Part I to amend the Regulations regarding the Post-market Surveillance of Medical Devices was posted June 15, 2019.
May 28, 2019
It has been some time coming but the speculation is over now. BC is the first province to switch patients from certain innovator biologics to their biosimilars.
May 24, 2019
Biosimilars no longer need to be reviewed by CADTH.
May 17, 2019
For industry, the path of the biologic prescription, once written, may see a number of influence points that affect market share, marketing plans, patient support programs (PSPs) and prescribers.